Can This Pharmaceutical Power Stay Healthy?

Before you go, we thought you'd like these...
Before you go close icon

Health-care powerhouse Johnson & Johnson has thrived for years on its diversity and safety, but the company's pharmaceuticals division has emerged as its best attraction for growth investors. Indeed, J&J's drug sales paved the way for another quarter of expectations-beating earnings, as the company released its second quarter data this week.

Star blockbuster immunology drug Remicade has long held down strong sales for J&J, and new upstarts such as diabetes-fighting drug Invokana are on their way to laying the groundwork for the company's future pharmaceutical success. Will this optimism be enough to keep this strong stock flying high in the future? Motley Fool contributor Dan Carroll tells you what you need to know about the performance at J&J's pharmaceutical division -- and what it means for your portfolio.

Johnson & Johnson's diversity and stability have made it one of the best bedrock stocks for any portfolio. This company's success has been a testament to the time-proven value of long-term investing, the best way to maximize your financial potential. The Motley Fool's special free report, "3 Stocks That Will Help You Retire Rich," names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.

The article Can This Pharmaceutical Power Stay Healthy? originally appeared on

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading